Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday.
A sign for Eli Lilly & Co. sits outside their corporate headquarters in Indianapolis on April 26, 2017.
Both donanemab and Leqembi are lab-made antibodies, administered by IV, that target one Alzheimer’s culprit, sticky amyloid buildup in the brain. And both drugs come with a serious safety concern — brain swelling or bleeding that in the Lilly study was linked to three deaths. Lilly’s study enrolled people ages 60 to 85 who were in early stages of Alzheimer’s. Half received once-a-month infusions of donanemab and half dummy infusions for 18 months.
How much difference does that make? It means donanemab slowed patients’ worsening by about four to seven months, the JAMA report concluded.Another way of measuring: Among the donanemab recipients with lower tau levels, 47% were considered stable a year into the study compared with 29% of those who got the dummy version.
Widera noted that the possibility of stopping donanemab treatment at least temporarily in people who respond well would help limit some of those challenges. For comparison, Leqembi is given by IV every two weeks and researchers didn’t test a similar stoppage.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Gene-Editing Tools Pave Way for New Alzheimer's TreatmentsTwo new studies using CRISPR gene editing offer potential new treatments for Alzheimer's disease.
Consulte Mais informação »
Second Alzheimer's drug in the pipeline promises to slow worsening but with safety concernAnother experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, according to a study of 1,700 patients. Eli Lilly and Co. is seeking Food and Drug Administration approval of donanemab.
Consulte Mais informação »
Groundbreaking new Alzheimer's drug promises to slow the diseaseThe FDA has approved a groundbreaking new Alzheimer’s drug that promises to slow the disease for patients. NBC10’s Randy Gyllenhaal has more on the benefits and the risks that patients should discuss with their doctors.
Consulte Mais informação »
Groundbreaking Alzheimer’s drug slows disease: A ‘new era’ for treatmentDonanemab has been linked to a 40% lower risk of progressing from mild cognitive impairment to mild dementia.
Consulte Mais informação »
Second Alzheimer's drug in pipeline can slow the disease by a few months but with safety riskNew research shows another experimental Alzheimer's drug can modestly slow patients' inevitable worsening.
Consulte Mais informação »
Second Alzheimer's drug in pipeline can slow the disease by a few months but with safety riskAnother experimental Alzheimer's drug can modestly slow patients' inevitable worsening — by about four to seven months, researchers reported Monday.
Consulte Mais informação »